

# Wolfgang P Fendler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9804016/publications.pdf>

Version: 2024-02-01

187  
papers

9,543  
citations

46984

47  
h-index

43868

91  
g-index

199  
all docs

199  
docs citations

199  
times ranked

6702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduction of emission time for [68Ga]Ga-PSMA PET/CT using the digital biograph vision: a phantom study. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2023, 67, .	0.4	8
2	Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. European Urology Oncology, 2022, 5, 544-552.	2.6	16
3	<sup>68</sup> Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the <sup>68</sup> Ga-FAPI PET Prospective Observational Trial. Journal of Nuclear Medicine, 2022, 63, 89-95.	2.8	58
4	Tumor Sink Effect in <sup>68</sup> Ga-PSMA-11 PET: Myth or Reality?. Journal of Nuclear Medicine, 2022, 63, 226-232.	2.8	42
5	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. Journal of Nuclear Medicine, 2022, 63, 396-398.	2.8	18
6	Diagnostic Performance of <sup>124</sup> I-Metaiodobenzylguanidine PET/CT in Patients with Pheochromocytoma. Journal of Nuclear Medicine, 2022, 63, 869-874.	2.8	8
7	Pitfalls and Common Findings in <sup>68</sup> Ga-FAPI PET: A Pictorial Analysis. Journal of Nuclear Medicine, 2022, 63, 890-896.	2.8	61
8	PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. Journal of Nuclear Medicine, 2022, 63, 76-80.	2.8	20
9	Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice. Journal of Nuclear Medicine, 2022, 63, 1357-1363.	2.8	1
10	Free-breathing 3D Stack of Stars GRE (StarVIBE) sequence for detecting pulmonary nodules in 18F-FDG PET/MRI. EJNMMI Physics, 2022, 9, 11.	1.3	2
11	A Role of PET/MR in Breast Cancer?. Seminars in Nuclear Medicine, 2022, 52, 611-618.	2.5	10
12	Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 2022, 14, 1727.	1.7	20
13	Radiation Protection and Occupational Exposure on <sup>68</sup> Ga-PSMA-11â€‘Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy. Journal of Nuclear Medicine, 2022, 63, 1349-1356.	2.8	4
14	Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. Journal of Nuclear Medicine, 2022, , jnumed.121.263072.	2.8	28
15	Effects of Antiâ€‘Tumor Necrosis Factor Therapy on Osteoblastic Activity at Sites of Inflammatory and Structural Lesions in Radiographic Axial Spondyloarthritis: A Prospective <sup>scp</sup> Proofâ€‘ofâ€‘Concept <sup>scp</sup> Study Using Positron Emission Tomography/Magnetic Resonance Imaging of the Sacroiliac Joints and Spine. Arthritis and Rheumatology, 2022, 74, 1497-1505.	2.9	6
16	A Role for PET/CT in Response Assessment of Malignant Pleural Mesothelioma. Seminars in Nuclear Medicine, 2022, 52, 816-823.	2.5	5
17	Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 1015-1024.	0.4	18
18	Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177â€‘prostate-specific membrane antigen ( <sup>177</sup> Lu-PSMA) after radium-223 ( <sup>223</sup> Ra): Interim analysis of the RALU study.. Journal of Clinical Oncology, 2022, 40, 5040-5040.	0.8	2

#	ARTICLE	IF	CITATIONS
19	18F-PSMA-11 Versus 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. <i>European Urology</i> , 2022, 82, 501-509.	0.9	16
20	Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4271-4281.	3.3	38
21	Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	3.2	45
22	Mechanisms of Resistance to Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.120.256263.	2.8	22
23	Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 812-821.	1.4	74
24	Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 191-194.	2.8	10
25	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 501-508.	3.3	30
26	PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1200-1210.	3.3	72
27	Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2021, 62, 675-678.	2.8	16
28	<sup>68</sup> Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1235-1241.	2.8	39
29	Evaluation of 18F-FDG PET/CT images acquired with a reduced scan time duration in lymphoma patients using the digital biograph vision. <i>BMC Cancer</i> , 2021, 21, 62.	1.1	16
30	[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors. <i>Oncology Research and Treatment</i> , 2021, 44, 400-407.	0.8	13
31	Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA. <i>Journal of Nuclear Medicine</i> , 2021, 62, 146-148.	2.8	15
32	Comparing lesion detection efficacy and image quality across different PET system generations to optimize the iodine-124 PET protocol for recurrent thyroid cancer. <i>EJNMMI Physics</i> , 2021, 8, 14.	1.3	11
33	Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS172-TPS172.	0.8	1
34	Imaging Inflammation with Positron Emission Tomography. <i>Biomedicines</i> , 2021, 9, 212.	1.4	24
35	Evaluation of [68Ga]Ga-PSMA PET/CT images acquired with a reduced scan time duration in prostate cancer patients using the digital biograph vision. <i>EJNMMI Research</i> , 2021, 11, 21.	1.1	10
36	Impact of PSMA PET/CT on SRT planning: Preliminary results from the randomized phase III trial NCT03582774.. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-30.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Prostate-specific Membrane Antigen <sup>18</sup> F-based Imaging of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 279-287.	1.6	17
38	We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 227-228.	1.6	0
39	Just another "Clever Hans"? Neural networks and FDG PET-CT to predict the outcome of patients with breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3141-3150.	3.3	23
40	Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy. , 2021, 9, e002262.		5
41	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021, 7, 238-240.	1.6	31
42	Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. <i>European Radiology</i> , 2021, 31, 8714-8724.	2.3	43
43	Nuclear Medicine beyond VISION. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262441.	2.8	5
44	REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262271.	2.8	0
45	2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2668-2669.	3.3	2
46	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021, 21, 512.	1.1	14
47	Determining the Axillary Nodal Status with 4 Current Imaging Modalities, Including <sup>18</sup> F-FDG PET/MRI, in Newly Diagnosed Breast Cancer: A Comparative Study Using Histopathology as the Reference Standard. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1677-1683.	2.8	13
48	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	3.6	38
49	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 101-111.	0.3	10
50	Prospective phase 2 trial of PSMA-targeted molecular Radiotherapy with <sup>177</sup> Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1440-1446.	2.8	37
51	Head-to-head intra-individual comparison of biodistribution and tumor uptake of <sup>68</sup> Ga-FAPI and <sup>18</sup> F-FDG PET/CT in cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4377-4385.	3.3	114
52	N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. <i>EJNMMI Research</i> , 2021, 11, 68.	1.1	2
53	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.3	2
54	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	1.0	16

#	ARTICLE	IF	CITATIONS
55	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 7431.	1.8	25
56	Safety of PSMA-Targeted Molecular Radioligand Therapy with <sup>177</sup> Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). Journal of Nuclear Medicine, 2021, 62, 1447-1456.	2.8	14
57	Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension. BMC Endocrine Disorders, 2021, 21, 161.	0.9	4
58	Nomograms to predict outcomes after <sup>177</sup> Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncology, The, 2021, 22, 1115-1125.	5.1	120
59	Initial clinical experience with <sup>90</sup> Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. Journal of Nuclear Medicine, 2021, , jnumed.121.262468.	2.8	64
60	Repeatability of <sup>68</sup> Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume. Journal of Nuclear Medicine, 2021, , jnumed.121.262528.	2.8	6
61	Diagnostic Accuracy of <sup>68</sup> Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection. JAMA Oncology, 2021, 7, 1635.	3.4	138
62	Theranostics in oncology: What radiologists want to know. European Journal of Radiology, 2021, 142, 109875.	1.2	2
63	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imagingâ€™ utilization of a short-pass filter to reduce technical pitfalls. Translational Andrology and Urology, 2021, 10, 3972-3985.	0.6	4
64	PSMA-Ligand PET for Early Castration-Resistant Prostate Cancer: A Retrospective Single-Center Study. Journal of Nuclear Medicine, 2021, 62, 88-91.	2.8	21
65	Assessment of right ventricular sympathetic dysfunction in patients with arrhythmogenic right ventricular cardiomyopathy: An <sup>123</sup> I-metaiodobenzylguanidine SPECT/CT study. Journal of Nuclear Cardiology, 2020, 27, 2402-2409.	1.4	8
66	Can the Injected Dose Be Reduced in <sup>68</sup> Ga-PSMA-11 PET/CT While Maintaining High Image Quality for Lesion Detection?. Journal of Nuclear Medicine, 2020, 61, 189-193.	2.8	19
67	Whole-Body Integrated [ <sup>68</sup> Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. Molecular Imaging and Biology, 2020, 22, 788-796.	1.3	39
68	Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. Journal of Nuclear Medicine, 2020, 61, 1037-1042.	2.8	19
69	Impact of <sup>68</sup> Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. European Urology Open Science, 2020, 19, e1215-e1216.	0.2	2
70	Outcome After <sup>68</sup> Ga-PSMA-11 versus Choline PET-Based Salvage Radiotherapy in Patients with Biochemical Recurrence of Prostate Cancer: A Matched-Pair Analysis. Cancers, 2020, 12, 3395.	1.7	7
71	Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. Current Opinion in Urology, 2020, Publish Ahead of Print, 635-640.	0.9	3
72	1896MO Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma. Annals of Oncology, 2020, 31, S1076-S1077.	0.6	0

#	ARTICLE	IF	CITATIONS
73	First-in-man intraoperative Cerenkov luminescence imaging for oligometastatic prostate cancer using <sup>68</sup> Ga-PSMA-11. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 3194-3195.	3.3	14
74	Impact of <sup>68</sup> Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1793-1799.	2.8	74
75	Efficacy and Safety of <sup>177</sup> Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	0.9	39
76	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 363-369.	0.5	16
77	Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by [ <sup>18</sup> F]FDG PET/CT and [ <sup>18</sup> F]FDG PET/MRI. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 183-191.	0.6	7
78	Intraoperative <sup>68</sup> Ga-PSMA Cerenkov Luminescence Imaging for Surgical Margins in Radical Prostatectomy: A Feasibility Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1500-1506.	2.8	32
79	<sup>18</sup> F-FDG-PET/MRI in the diagnostic work-up of limbic encephalitis. <i>PLoS ONE</i> , 2020, 15, e0227906.	1.1	29
80	Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1153-1160.	2.8	94
81	PSMA-positive nodal recurrence in prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 637-646.	1.0	7
82	In vivo biodistribution of calcium phosphate nanoparticles after intravascular, intramuscular, intratumoral, and soft tissue administration in mice investigated by small animal PET/CT. <i>Acta Biomaterialia</i> , 2020, 109, 244-253.	4.1	37
83	Prospective evaluation of whole-body MRI and <sup>18</sup> F-FDG PET/MRI in N and M staging of primary breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2816-2825.	3.3	23
84	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from <sup>68</sup> Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. <i>BMC Cancer</i> , 2020, 20, 326.	1.1	38
85	PSMA-PET identifies PCWG3 target populations with high concordance however superior reproducibility when compared to conventional imaging. <i>Nuklearmedizin - Nuclear Medicine</i> , 2020, 59, .	0.3	1
86	Imaging inflammation after myocardial infarction: implications for prognosis and therapeutic guidance. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 35-50.	0.4	3
87	SAT0365...EFFECTS OF ANTI-TNF-THERAPY ON OSTEOBLASTIC ACTIVITY IN ANKYLOSING SPONDYLITIS " RESULTS FROM A PROSPECTIVE STUDY USING PET-MRI OF SIJ AND SPINE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1129.2-1130.	0.5	0
88	Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 227-233.	2.8	61
89	Salvage PRRT with <sup>177</sup> Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. <i>BMC Cancer</i> , 2019, 19, 788.	1.1	64
90	EANM procedure guidelines for radionuclide therapy with <sup>177</sup> Lu-labelled PSMA-ligands ( <sup>177</sup> Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265



#	ARTICLE	IF	CITATIONS
91	18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology, The</i> , 2019, 20, 1286-1294.	5.1	338
92	What is the best PET target for early biochemical recurrence of prostate cancer?â€“Authorsâ€™ reply. <i>Lancet Oncology, The</i> , 2019, 20, e609-e610.	5.1	4
93	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	3.2	190
94	Improving <sup>68</sup> Ga-PSMA PET/MRI of the Prostate with Unrenormalized Absolute Scatter Correction. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1642-1648.	2.8	21
95	Molecular Imaging for Primary Staging of Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 271-279.	2.5	9
96	Assessment of <sup>68</sup> Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 856.	3.4	493
97	<sup>18</sup> F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1537-1542.	2.8	19
98	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162.	2.6	29
99	Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. <i>BMC Cancer</i> , 2019, 19, 18.	1.1	86
100	Metaanalysis of <sup>68</sup> Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology. <i>Journal of Nuclear Medicine</i> , 2019, 60, 786-793.	2.8	169
101	Impact of <sup>68</sup> Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. <i>Journal of Nuclear Medicine</i> , 2019, 60, 963-970.	2.8	44
102	<sup>68</sup> Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. <i>Journal of Urology</i> , 2019, 202, 1174-1181.	0.2	33
103	RESIST-PC phase 2 trial: 177Lu-PSMA-617 radionuclide therapy for metastatic castrate-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5028-5028.	0.8	11
104	Prospective head-to-head comparison of 18F-fluciclovine and 68Ga-PSMA-11 PET/CT for localization of prostate cancer biochemical recurrence after primary prostatectomy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 15-15.	0.8	8
105	Randomized phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS136-TPS136.	0.8	3
106	Textural analysis of DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, .	0.3	0
107	Prospective head-to-head comparative phase 3 study between <sup>18</sup> F-fluciclovine and <sup>68</sup> Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5014-5014.	0.8	0
108	Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS5101-TPS5101.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Reply by Authors. Journal of Urology, 2019, 202, 1181-1181.	0.2	0
110	Reply: Comparison of <sup>68</sup> Ga-PSMA-11 and <sup>18</sup> F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence: Prospective Trial Is on Its Way. Journal of Nuclear Medicine, 2018, 59, 861-861.	2.8	7
111	Effect of stroke thrombolysis predicted by distal vessel occlusion detection. Neurology, 2018, 90, e1742-e1750.	1.5	7
112	Potential Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1714-1721.	2.8	81
113	Neoadjuvant chemoradiation for esophageal cancer. Strahlentherapie Und Onkologie, 2018, 194, 435-443.	1.0	5
114	Comparison of <sup>68</sup> Ga-PSMA-11 and <sup>18</sup> F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence. Journal of Nuclear Medicine, 2018, 59, 789-794.	2.8	68
115	Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. Prostate, 2018, 78, 775-789.	1.2	35
116	Detection Threshold and Reproducibility of <sup>68</sup> Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. Journal of Nuclear Medicine, 2018, 59, 1392-1397.	2.8	21
117	A New Type of Prostate Cancer Imaging: Will <sup>64</sup> CuCl <sub>2</sub> PET/CT Flourish or Vanish?. Journal of Nuclear Medicine, 2018, 59, 442-443.	2.8	5
118	Impact of <sup>68</sup> Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. Journal of Nuclear Medicine, 2018, 59, 434-441.	2.8	113
119	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed mITNM Classification for the Interpretation of PSMA-Ligand PET/CT. Journal of Nuclear Medicine, 2018, 59, 469-478.	2.8	372
120	<sup>68</sup> Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Journal of Nuclear Medicine, 2018, 59, 230-237.	2.8	226
121	Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Research, 2018, 8, 96.	1.1	58
122	<sup>68</sup> Ga-PSMA PET/CT Mapping of Prostate Cancer at Initial Staging: Potential Impact on Definitive Radiation Therapy Planning. International Journal of Radiation Oncology Biology Physics, 2018, 102, S162.	0.4	0
123	EP-1551: Outcome after PSMA PET based RT in patients with biochemical recurrence or persistence after surgery. Radiotherapy and Oncology, 2018, 127, S837.	0.3	0
124	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. American Journal of Roentgenology, 2018, 211, 286-294.	1.0	25
125	Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiation Oncology, 2018, 13, 37.	1.2	54
126	Accuracy of <sup>68</sup> Ga-PSMA11 PET/CT on recurrent prostate cancer: Preliminary results from a phase 2/3 prospective trial.. Journal of Clinical Oncology, 2018, 36, 5001-5001.	0.8	6



#	ARTICLE	IF	CITATIONS
127	Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer. <i>European Radiology</i> , 2017, 27, 113-119.	2.3	20
128	A PET for All Seasons: 18 F-Fluorodeoxyglucose to Characterize Inflammation and Malignancy in Retroperitoneal Fibrosis?. <i>European Urology</i> , 2017, 71, 934-935.	0.9	0
129	The Impact of Somatostatin Receptor-Targeted PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 756-761.	2.8	158
130	NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)-Targeted Theranostics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 934-935.	2.8	5
131	<sup>68</sup> Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024.	3.3	589
132	<sup>68</sup> Ga-PSMA-11 PET/CT Interobserver Agreement for Prostate Cancer Assessments: An International Multicenter Prospective Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1617-1623.	2.8	111
133	Most of the Intended Management Changes After <sup>68</sup> Ga-DOTATATE PET/CT Are Implemented. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1793-1796.	2.8	24
134	Establishing <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1786-1792.	2.8	35
135	More $\hat{\mu}$ Than $\hat{\sigma}^2$ for Prostate Cancer?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1709-1710.	2.8	12
136	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	2.8	163
137	EP-1323: Role of <sup>68</sup> Ga-PSMA PET/CT in radiotherapy for prostate cancer: A single centre experience. <i>Radiotherapy and Oncology</i> , 2017, 123, S709-S710.	0.3	0
138	PSMA Ligands for PET Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1545-1552.	2.8	165
139	Targeted Prostate Biopsy Using <sup>68</sup> Ga Gallium PSMA-PET/CT for Image Guidance. <i>Urology Case Reports</i> , 2017, 14, 11-14.	0.1	25
140	PSMA ligands in prostate cancer - Probe optimization and theranostic applications. <i>Methods</i> , 2017, 130, 42-50.	1.9	43
141	<sup>177</sup> Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	2.8	159
142	[ <sup>18</sup> F]FDG PET accurately differentiates infected and non-infected non-unions after fracture fixation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 432-440.	3.3	20
143	German Multicenter Study Investigating <sup>177</sup> Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 85-90.	2.8	646
144	<sup>68</sup> Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 307-311.	2.8	27

#	ARTICLE	IF	CITATIONS
145	Radiation Dosimetry for <sup>177</sup> Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. Journal of Nuclear Medicine, 2017, 58, 445-450.	2.8	144
146	Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma. Nuklearmedizin - NuclearMedicine, 2017, 56, 211-218.	0.3	3
147	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. Radiation Oncology, 2017, 12, 176.	1.2	34
148	Preliminary experience with dosimetry, response and patient reported outcome after <sup>177</sup> Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget, 2017, 8, 3581-3590.	0.8	172
149	Safety and efficacy of <sup>177</sup> Lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.. Journal of Clinical Oncology, 2017, 35, 155-155.	0.8	2
150	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. Oncotarget, 2017, 8, 44131-44140.	0.8	16
151	Salvage lymph node dissection after <sup>68</sup> Ga-PSMA or <sup>18</sup> F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget, 2017, 8, 84180-84192.	0.8	41
152	Have we overcome choline PET/CT for early detection of prostate cancer recurrence?. Nuclear Medicine Communications, 2016, 37, 567-569.	0.5	1
153	<sup>123</sup> I: Impact of the primary tumor metabolic volume (PT-MV) changes in the course of multimodality treatment on overall survival in patients with locally-advanced non-small cell lung cancer. Journal of Thoracic Oncology, 2016, 11, S109.	0.5	0
154	Serial <sup>18</sup> F-FET PET Imaging of Primarily <sup>18</sup> F-FET-“Negative Glioma: Does It Make Sense?. Journal of Nuclear Medicine, 2016, 57, 1177-1182.	2.8	56
155	Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients. Journal of Nuclear Medicine, 2016, 57, 517-523.	2.8	48
156	Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer. Expert Review of Molecular Diagnostics, 2016, 16, 1177-1188.	1.5	38
157	<sup>68</sup> Ga-labeled Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Imaging: The New Kid on the Block-“Early or Too Early to Draw Conclusions?. European Urology, 2016, 70, 938-940.	0.9	13
158	Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites. Journal of Nuclear Medicine, 2016, 57, 2016-2021.	2.8	35
159	Reduced Periprocedural Analgesia After Replacement of Water for Injection with Glucose 5% Solution as the Infusion Medium for <sup>90</sup> Y-Resin Microspheres. Journal of Nuclear Medicine, 2016, 57, 1679-1684.	2.8	15
160	Distribution of prostate nodes: a PET/CT-derived anatomic atlas of prostate cancer patients before and after surgical treatment. Radiation Oncology, 2016, 11, 37.	1.2	15
161	<sup>68</sup> Ga-PSMA PET/CT Detects the Location and Extent of Primary Prostate Cancer. Journal of Nuclear Medicine, 2016, 57, 1720-1725.	2.8	179
162	PD42-11 <sup>68</sup> Ga-PSMA PET/CT PROVIDES ACCURATE STAGING OF LYMPH NODE REGIONS PRIOR TO LYMPH NODE DISSECTION IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 2016, 195, .	0.2	0

#	ARTICLE	IF	CITATIONS
163	68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. <i>Cancer Imaging</i> , 2016, 16, 14.	1.2	171
164	PET imaging in prostate cancer, future trends: PSMA ligands. <i>Clinical and Translational Imaging</i> , 2016, 4, 467-472.	1.1	6
165	68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer. <i>European Urology</i> , 2016, 70, 553-557.	0.9	248
166	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 355-360.	2.8	22
167	The diagnostic value of [18F]FDG PET for the detection of chronic osteomyelitis and implant-associated infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 749-761.	3.3	56
168	Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51.	3.3	244
169	Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy. <i>PLoS ONE</i> , 2015, 10, e0132809.	1.1	18
170	PET Response Criteria in Solid Tumors Predicts Progression-Free Survival and Time to Local or Distant Progression After Chemotherapy with Regional Hyperthermia for Soft-Tissue Sarcoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 530-537.	2.8	31
171	Safety of Radioembolization with 90Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels. <i>CardioVascular and Interventional Radiology</i> , 2015, 38, 946-956.	0.9	9
172	Impact of 68Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum. <i>Annals of Surgical Oncology</i> , 2015, 22, 164-171.	0.7	41
173	Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. <i>European Radiology</i> , 2015, 25, 2693-2700.	2.3	22
174	Evaluation of several FDG PET parameters for prediction of soft tissue tumour grade at primary diagnosis and recurrence. <i>European Radiology</i> , 2015, 25, 2214-2221.	2.3	23
175	Positron emission tomography in pediatric and adult sarcoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 83-93.	1.1	0
176	Systematic Evaluation of Tumoral <sup>99m</sup> Tc-MAA Uptake Using SPECT and SPECT/CT in 502 Patients Before <sup>90</sup> Y Radioembolization. <i>Journal of Nuclear Medicine</i> , 2015, 56, 333-338.	2.8	21
177	Predictive Value of <sup>99m</sup> Tc-MAA SPECT for <sup>90</sup> Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1654-1660.	2.8	74
178	Correlation of Perfusion MRI and 18F-FDG PET Imaging Biomarkers for Monitoring Regorafenib Therapy in Experimental Colon Carcinomas with Immunohistochemical Validation. <i>PLoS ONE</i> , 2015, 10, e0115543.	1.1	6
179	Nuclear medicine and multimodality imaging of pediatric neuroblastoma. <i>Pediatric Radiology</i> , 2013, 43, 418-427.	1.1	62
180	High 123I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1701-1710.	3.3	30

#	ARTICLE	IF	CITATIONS
181	The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 356-363.	3.3	65
182	Virus-associated activation of innate immunity induces rapid disruption of Peyer's patches in mice. <i>Blood</i> , 2013, 122, 2591-2599.	0.6	6
183	Validation of Several SUV-Based Parameters Derived from <sup>18</sup> F-FDG PET for Prediction of Survival After SIRT of Hepatic Metastases from Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1202-1208.	2.8	78
184	Temporal factors in violence related injuries—An 11-year trend analysis of violence-related injuries from a Swiss Emergency Department. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 830-833.	1.0	4
185	Diagnostic value of combined 18F-FDG PET/MRI for staging and restaging in paediatric oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1745-1755.	3.3	50
186	CD103 is a hallmark of tumor-infiltrating regulatory T cells. <i>International Journal of Cancer</i> , 2011, 129, 2417-2426.	2.3	104
187	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0